Aldeyra Therapeutics, Inc. (ALDX) Stock

Aldeyra Therapeutics, Inc. (ALDX) is a Healthcare stock trading at $1.96 (as of 2026-06-18), with a market capitalization of $112.20M and a trailing P/E of -3.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aldeyra Therapeutics, Inc. is a biotechnology company developing and commercializing medicines targeting immune-mediated ocular and systemic diseases. Its pipeline includes RASP modulators such as reproxalap and ADX-629 in late- and mid-stage clinical development for conditions including dry eye disease, allergic conjunctivitis, psoriasis, asthma and COVID-19, as well as ADX-2191, a dihydrofolate reductase inhibitor, and other programs under development through collaborations.

Valuation — source: SEC EDGAR (first-party)
Price	$1.96
Market Cap	$112.20M
P/E Ratio	-3.9
EV / EBITDA	-2.0
Price / Book	2.52
Price / Sales	36.54
DCF Value (model)	$-8.52
DCF Upside vs Price	-535.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.32M
Net Margin	-1018.3%
Return on Equity	-64.9%
Debt / Equity	0.36
Current Ratio	2.72
Revenue Growth (YoY)	-42.6%
EPS Growth (YoY)	-64.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.70 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-118.7%
vs Industry	-123.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($19.16M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Todd C. Brady
Employees	9
Country	US
IPO Date	2014-05-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.